Related Experiment Video
Updated: Aug 4, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
ADCs or: How I Learned to Stop Worrying and Love Chemotherapy
Avantika Gupta1, Joshua Z Drago2,3, Sarat Chandarlapaty1,2,3
1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract:
Antibody-drug conjugates are transforming cancer treatment, and payload characteristics are emerging as crucial determinants of clinical activity. As exemplified by Weng and colleagues, advancements in the linker and payload chemistry may provide the next evolutionary step in enabling this class of drugs to overcome chemoresistance and deliver even more profound responses. See related article by Weng et al., p. 950 (2).
More Related Videos
04:48Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists